Physician profile
Edwin Seelye
NPI 1902253651
$751.10
in general payments reported to CMS, 2019-2025
8 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $177 · 2021: $420 · 2022: $155.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $285.91 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $227.04 | 2020-2022 | |
| Pfizer INC. | $78.79 | 2020-2021 | |
| Gilead Sciences, INC. | $58.25 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $47.07 | 2020-2022 | |
| Astrazeneca Pharmaceuticals Lp | $19.53 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $18.96 | 2021 | |
| Abbvie INC. | $15.55 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edwin Seelye listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.